{
    "id": "f98d7d80-ecf4-4cb8-9a9b-5ffa043fe894",
    "indications": "Drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: Prevent pregnancy. (1.1) Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. (1.2) Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. (1.3) Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. (1.4)",
    "contraindications": "Take one tablet daily by mouth at the      same time every day. ( 2.1 ) Tablets must be taken in the order      directed on the blister. ( 2.1 )",
    "warningsAndPrecautions": "Drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets are available in 28 tablets blister containing 28 tablets packed in a pouch (NDC 68180-894-71). Such three pouches are packaged in a carton (NDC 68180-894-73).\n                        Each blister contains 28 film-coated tablets in the following order:\n                        \n                           24 pink, round      shaped, biconvex film-coated tablets debossed with \"LU\" on one side      and \"J61\" on other side each containing 3 mg drospirenone, 0.02 mg      ethinyl estradiol and 0.451 mg levomefolate calcium.\n                           4 light      orange, round shaped, biconvex film-coated tablets debossed with \"LU\"      on one side and \"J62\" on other side each containing 0.451 mg      levomefolate calcium.",
    "adverseReactions": "Drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     Renal impairment\n                     Adrenal insufficiency\n                     A high risk of arterial or venous      thrombotic diseases. Examples include women who are known to:\n                           Smoke, if over age 35 [see Boxed      Warning and Warnings And Precautions (5.1)]\n                           \n                           Have deep vein thrombosis or pulmonary      embolism, now or in the past [see Warnings And Precautions (5.1)]\n                           \n                           Have cerebrovascular disease[see      Warnings And Precautions (5.1)]\n                           \n                           Have coronary artery disease[see      Warnings And Precautions (5.1)]\n                           \n                           Have thrombogenic valvular or      thrombogenic rhythm diseases of the heart (for example, subacute bacterial      endocarditis with valvular disease, or atrial fibrillation) [see      Warnings And Precautions (5.1)]\n                           \n                           Have inherited or acquired      hypercoagulopathies [see Warnings And Precautions (5.1)]\n                           \n                           Have uncontrolled hypertension [see      Warnings And Precautions (5.6)]\n                           \n                           Have diabetes mellitus with vascular      disease [see Warnings And Precautions (5.8)]\n                           \n                           Have headaches with focal neurological      symptoms or have migraine headaches with or without aura if over age 35 [see      Warnings And Precautions (5.9)]\n                           \n                        \n                     \n                     Undiagnosed abnormal uterine bleeding [see      Warnings And Precautions (5.10)]\n                     \n                     Current diagnosis of, or history of,      breast cancer, which may be hormone-sensitive [see Warnings And      Precautions (5.3)]\n                     \n                     Liver tumors, benign or malignant, or      liver disease [see Warnings And Precautions (5.4)      and Use In Specific Populations (8.7)]\n                     \n                     Use of Hepatitis C drug combinations      containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir      due to the potential for ALT elevations [see Warnings And Precautions (5.5)      and Drug Interactions (7.3)].",
    "ingredients": [],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium",
    "effectiveTime": "20250414"
}